Taysha Gene Therapies Insider Trades
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 12 · $6.66M
- Shares bought / sold
- 0 / 1.37M
- Net activity
- Net selling $6.7 million
Taysha Gene Therapies insider activity
Over the last 12 months, Taysha Gene Therapies insiders reported 25 transactions on SEC Form 4: 0 open-market purchases and 12 sales. Insiders bought $0 and sold $6.7 million worth of stock, for net insider selling of $6.7 million. The largest seller was Nagendran Sukumar, with $5.3 million in reported sales.
The most recent filing shows Nagendran Sukumar (President and Head of R&D) selling 200,000 shares at $6.24 on Jul 10, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put TSHA's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
TSHA insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jul 10, 2026 | Nagendran SukumarPresident and Head of R&D | Sale | 200,000 | $1.25M | Form 4 |
| Jun 1, 2026 | Sepp-Lorenzino LauraDirector | Award | 21,335 | — | Form 4 |
| Jun 1, 2026 | Long Alison SDirector | Award | 21,335 | — | Form 4 |
| Jun 1, 2026 | Donenberg Phillip B.Director | Award | 21,335 | — | Form 4 |
| Jun 1, 2026 | Stalfort John A IIIDirector | Award | 21,335 | — | Form 4 |
| Apr 10, 2026 | Nagendran SukumarPresident and Head of R&D | Sale | 200,000 | $892.00K | Form 4 |
| Apr 10, 2026 | Nagendran SukumarPresident and Head of R&D | Option exercise | 19,021 | $32.53K | Form 4 |
| Feb 4, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sale | 1,655 | $7.48K | Form 4 |
| Jan 26, 2026 | Nagendran SukumarPresident and Head of R&D | Sale | 26,918 | $124.09K | Form 4 |
| Jan 26, 2026 | Nolan Sean P.Chief Executive Officer | Sale | 41,312 | $190.45K | Form 4 |
| Jan 26, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sale | 23,849 | $109.94K | Form 4 |
| Jan 23, 2026 | Nagendran SukumarPresident and Head of R&D | Sale | 89,132 | $423.38K | Form 4 |
| Jan 23, 2026 | Nolan Sean P.Chief Executive Officer | Sale | 136,789 | $649.75K | Form 4 |
| Jan 23, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Sale | 78,968 | $375.10K | Form 4 |
| Jan 12, 2026 | Nagendran SukumarPresident and Head of R&D | Award | 427,000 | — | Form 4 |
| Jan 12, 2026 | Nagendran SukumarPresident and Head of R&D | Sale | 200,000 | $942.00K | Form 4 |
| Jan 12, 2026 | Nagendran SukumarPresident and Head of R&D | Option exercise | 88,676 | $151.64K | Form 4 |
| Jan 12, 2026 | Nagendran SukumarPresident and Head of R&D | Option exercise | 111,324 | $77.80K | Form 4 |
| Jan 12, 2026 | Nolan Sean P.Chief Executive Officer | Award | 1,008,000 | — | Form 4 |
| Jan 12, 2026 | Alam KamranCHIEF FINANCIAL OFFICER | Award | 359,000 | — | Form 4 |
| Dec 1, 2025 | Nagendran SukumarPresident and Head of R&D | Sale | 260,047 | $1.17M | Form 4 |
| Dec 1, 2025 | Nagendran SukumarPresident and Head of R&D | Option exercise | 260,047 | $444.68K | Form 4 |
| Nov 28, 2025 | Nagendran SukumarPresident and Head of R&D | Sale | 110,125 | $523.09K | Form 4 |
| Nov 28, 2025 | Nagendran SukumarPresident and Head of R&D | Option exercise | 39,953 | $68.32K | Form 4 |
| Nov 28, 2025 | Nagendran SukumarPresident and Head of R&D | Option exercise | 70,172 | $49.04K | Form 4 |
| Sep 10, 2025 | Nagendran SukumarPresident and Head of R&D | Sale | 200,000 | $646.00K | Form 4 |
| Sep 10, 2025 | Nagendran SukumarPresident and Head of R&D | Option exercise | 41,150 | $28.76K | Form 4 |
| Aug 21, 2025 | Alam KamranCHIEF FINANCIAL OFFICER | Sale | 54,491 | $155.30K | Form 4 |
| Aug 21, 2025 | Nagendran SukumarPresident and Head of R&D | Sale | 57,054 | $162.60K | Form 4 |
| Jun 2, 2025 | Sepp-Lorenzino LauraDirector | Award | 56,623 | — | Form 4 |
| Jun 2, 2025 | Long Alison SDirector | Award | 56,623 | — | Form 4 |
| Jun 2, 2025 | Stalfort John A IIIDirector | Award | 56,623 | — | Form 4 |
| Jun 2, 2025 | Donenberg Phillip B.Director | Award | 56,623 | — | Form 4 |
| May 30, 2025 | Manning Paul B10% Owner | Buy | 750,000 | $2.06M | Form 4 |
| Mar 11, 2025 | Alam KamranCHIEF FINANCIAL OFFICER | Tax withholding | 29,843 | $50.43K | Form 4 |
| Jan 2, 2025 | Alam KamranCHIEF FINANCIAL OFFICER | Award | 431,000 | — | Form 4 |
| Jan 2, 2025 | Nagendran SukumarPresident and Head of R&D | Award | 324,500 | — | Form 4 |
| Jan 2, 2025 | Nolan Sean P.Chief Executive Officer | Award | 892,500 | — | Form 4 |
| Jun 27, 2024 | Manning Paul B10% Owner | Buy | 1,333,333 | $3.00M | Form 4 |
| May 29, 2024 | Sepp-Lorenzino LauraDirector | Award | 49,220 | — | Form 4 |
| May 29, 2024 | Donenberg Phillip B.Director | Award | 49,220 | — | Form 4 |
| May 29, 2024 | Long Alison SDirector | Award | 49,220 | — | Form 4 |
| May 29, 2024 | Stalfort John A IIIDirector | Award | 49,220 | — | Form 4 |
| Feb 2, 2024 | Alam KamranCHIEF FINANCIAL OFFICER | Tax withholding | 1,288 | $1.94K | Form 4 |
| Jan 2, 2024 | Nolan Sean P.Chief Executive Officer | Award | 1,184,688 | — | Form 4 |
| Jan 2, 2024 | Alam KamranChief Financial Officer | Award | 590,413 | — | Form 4 |
| Jan 2, 2024 | Nagendran SukumarPresident and Head of R&D | Award | 863,617 | — | Form 4 |
| Nov 17, 2023 | Manning Paul B10% Owner | Buy | 100,000 | $163.00K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4